Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion
- PMID: 8709310
Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion
Abstract
Purpose: We investigated the effect on survival of transitional cell carcinoma of the prostatic urethra, ducts and stroma, and determined the difference between prostatic stromal involvement occurring via direct extension through the bladder wall versus stromal invasion arising intraurethrally.
Materials and methods: Between August 1971 and December 1989, 489 men underwent radical cystoprostatectomy for transitional cell carcinoma, including 143 (29.2%) identified with prostate involvement by transitional cell carcinoma, in the cystectomy specimen. Patients were separated into 2 groups: 1-19 in whom the primary bladder tumor extended full thickness through the bladder wall to invade the prostate (classified as P4a) and 2-124 in whom prostate involvement arose from within the prostatic urethra.
Results: Five-year recurrence-free and overall survival rates were 25 and 21%, respectively, in group 1 versus 64 and 55%, respectively, in group 2. In the 124 patients in group 2 survival rates were similar for those with prostatic urethral tumors or carcinoma in situ and ductal tumors (no stromal invasion). Five-year overall survival rates without and with stromal invasion were 71 and 36%, respectively (p < 0.0001). Transitional cell carcinoma of the prostatic urethra or ducts does not alter survival predicted by primary bladder stage alone. Prostatic stromal invasion arising intraurethrally significantly decreases survival, which varies based on primary bladder stage (64.6% in stage P1, 30.8% in stages P2/P3a and 13.6% in stage P3b, p = 0.0001). P1 bladder tumors with prostatic stromal invasion arising intraurethrally had a significantly higher survival rate than P4a tumors (64.6 versus 21%, p = 0.0001). P3b bladder tumors with stromal invasion had a survival rate similar to that of P4a tumors (p = 0.78).
Conclusions: Prostatic urethral or ductal transitional cell carcinoma does not alter survival determined by primary bladder stage alone and it should not be classified as P4a. Prostatic stromal involvement arising intraurethrally significantly decreases survival predicted by primary bladder stage alone. P1 bladder tumors with prostatic stromal invasion arising intraurethrally have a significantly higher survival rate than P4a tumors and they should be separately classified as P1str. Muscle invasive (P2/P3a) bladder tumors with stromal invasion have a higher survival rate than P4a tumors (no statistical significance) and they should be designated separately (that is P2str). P3b bladder tumors with prostatic stromal invasion arising intraurethrally are indistinguishable from P4a tumors.
Comment in
-
A new staging system for transitional cell carcinoma involvement of the prostate and reconfirmation studies of intravesical therapy for superficial bladder cancer.J Urol. 1996 Sep;156(3):972-4. doi: 10.1016/s0022-5347(01)65675-1. J Urol. 1996. PMID: 8709376 No abstract available.
Similar articles
-
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance.Hum Pathol. 2006 Jun;37(6):726-34. doi: 10.1016/j.humpath.2006.01.027. Hum Pathol. 2006. PMID: 16733214
-
Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.J Urol. 2005 Apr;173(4):1163-8. doi: 10.1097/01.ju.0000149679.56884.0f. J Urol. 2005. PMID: 15758728
-
The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.Urol Int. 2009;82(3):306-11. doi: 10.1159/000209363. Epub 2009 May 11. Urol Int. 2009. PMID: 19440019
-
Urothelial carcinoma in the prostatic urethra and prostate: current controversies.Expert Rev Anticancer Ther. 2007 Mar;7(3):383-90. doi: 10.1586/14737140.7.3.383. Expert Rev Anticancer Ther. 2007. PMID: 17338657 Review.
-
Dilemmas in the treatment of urothelial cancers of the prostate.Urol Oncol. 2009 Jul-Aug;27(4):352-7. doi: 10.1016/j.urolonc.2007.12.010. Epub 2008 Apr 24. Urol Oncol. 2009. PMID: 18439852 Review.
Cited by
-
Treatment of bladder cancer in cardiac transplant patients.Int Urol Nephrol. 2006;38(3-4):477-9. doi: 10.1007/s11255-005-4978-3. Int Urol Nephrol. 2006. PMID: 17115247
-
Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra.Bladder Cancer. 2021 May 25;7(2):213-220. doi: 10.3233/BLC-201516. eCollection 2021. Bladder Cancer. 2021. PMID: 38994530 Free PMC article.
-
Seminal vesicle involvement by urothelial carcinoma in situ of the bladder with mucosal spread pattern: a case report.Korean J Urol. 2012 May;53(5):368-70. doi: 10.4111/kju.2012.53.5.368. Epub 2012 May 18. Korean J Urol. 2012. PMID: 22670198 Free PMC article.
-
Concomitant bladder cancer and prostate cancer: challenges and controversies.Nat Rev Urol. 2017 Oct;14(10):620-629. doi: 10.1038/nrurol.2017.124. Epub 2017 Aug 16. Nat Rev Urol. 2017. PMID: 28813037 Review.
-
Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy.J Clin Urol. 2016 Nov;9(6):404-408. doi: 10.1177/2051415815617876. Epub 2016 Nov 2. J Clin Urol. 2016. PMID: 27818773 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical